Nanexa jumps 114% on up to €1.17bn Novo Nordisk licensing deal

Nanexa shares rose 114% on Sept 25, 2026, on reports it will license its injection technology to Novo Nordisk for up to €1.17bn ($1.33bn). For savers and investors, that total is a ceiling, not cash in hand: payment depends on milestones yet to be met.